Delivery Order SPE2DB22D1202-SPE2DB25FVBK1
- Not listed
- The Defense Logistics Agency awarded a $11,830 delivery order to AmerisourceBergen Drug Corp for SKYRIZI 360 MG/2.4 ML on-body injector units on July 29, 2025, with an ultimate completion date of August 19, 2025. This firm fixed price delivery order, which was competitively awarded with no set-aside designation, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. SKYRIZI is a prescription biologic medication used to treat autoimmune conditions, and...
- The Defense Logistics Agency awarded a $11,830 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of SKYRIZI 360 mg/2.4 mL on-body injectors. The order, with an ultimate completion date of September 5, 2025, represents a non-set-aside competitive award and will be performed at the contractor's facility in Conshohocken, Pennsylvania. SKYRIZI is a biologic immunosuppressant used in the treatment of plaque psoriasis and other inflammatory conditions,...
- The Defense Logistics Agency awarded a $11,830 firm fixed price delivery order to AmerisourceBergen Drug Corp for SKYRIZI 360 mg/2.4 ml on-body injector units, with a completion deadline of June 23, 2025. This non-competitive delivery order was awarded on May 30, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. SKYRIZI is a biologic medication used to treat inflammatory skin conditions, and this order represents a routine...
- The Defense Logistics Agency awarded a $25,209.26 delivery order to AmerisourceBergen Drug Corp for SKYRIZI 360 MG/2.4 ML on-body injectors on April 29, 2025, with a completion date of May 20, 2025. This firm fixed price, non-set-aside contract was issued under a competitive procurement process and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. SKYRIZI is a biologic treatment used for dermatological conditions, representing part of the company's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,830.00 to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/mL pen injectors on June 2, 2025, with completion expected by June 3, 2025. This firm fixed-price delivery order represents a non-competitive award issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.99 million and extending through December 2026. SKYRIZI is a biologic immunosuppressant used to...
- The Defense Logistics Agency awarded a delivery order valued at $11,830.00 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 360 mg/2.4 ml on-body injectors. This firm fixed-price, competitively awarded contract was issued on July 29, 2025, with an ultimate completion date of August 19, 2025. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania. SKYRIZI is a biologic immunosuppressant medication used in the treatment of moderate-to-severe plaque psoriasis...
- The Defense Logistics Agency awarded a delivery order valued at $11,830.00 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 360 mg/2.4 mL on-body injectors on August 21, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion date of September 12, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. SKYRIZI is a biologic immunosuppressant medication used to treat...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 26, 2025, for the supply of SKYRIZI 180 mg/1.2 mL on-body injectors valued at $11,830.00. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award based on open competition. The contract will be completed by August 15, 2025, with performance occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. SKYRIZI is a biologic...
- The Defense Logistics Agency awarded a $11,830 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for the supply of SKYRIZI 180 MG/1.2 ML on-body injectors with a completion deadline of October 15, 2025. SKYRIZI is a biologic medication used in the treatment of immune-mediated inflammatory diseases. This delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of SKYRIZI 360 mg/2.4 ml on-body injectors valued at $11,830.00. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under open competition. The contract is set to complete by September 18, 2025, with performance executed from AmerisourceBergen's Conshohocken, Pennsylvania headquarters. This delivery order...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVBK1Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $11,830.00 on June 4, 2025, for the supply of SKYRIZI 360 mg/2.4 mL on-body injector units. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of June 26, 2025, to be performed at AmerisourceBergen's Conshohocken, Pennsylvania location. SKYRIZI is a biologic immunosuppressant used to treat moderate to severe plaque psoriasis and other inflammatory conditions, and this delivery order represents a routine pharmaceutical procurement through DLA's medical supply chain supporting federal healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's parent Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical federal medical vendor, AmerisourceBergen supplies a comprehensive range of brand-name and generic medications, vaccines, and specialized medical supplies to support military healthcare programs and other government healthcare systems worldwide. The competitively awarded IDC vehicle enables the company to fulfill diverse pharmaceutical procurement needs across multiple therapeutic domains for the Defense Health Agency, U.S. Coast Guard, and related federal customers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.8k | 6/4/25 |